Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 3/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17593270 | 0.78 | BTK (0.36) | HTTALDH1A1POLBKMT2ARAB9A | |
| SCHEMBL22438619 | 0.78 | ALDH1A1 (0.36) | ALDH1A1POLBCYP1A2KMT2AMAPT | |
| SCHEMBL911440 | 0.77 | HPGD (0.40) | HTTALDH1A1POLBTDP1SIRT2 | |
| SCHEMBL2969903 | 0.77 | CYP1A2 (0.41) | POLBTDP1NQO2SIRT2SIRT1 | |
| SCHEMBL30207735 | 0.77 | CYP1A2 (0.41) | POLBTDP1NQO2SIRT2SIRT1 | |
| SCHEMBL29581181 | 0.77 | HPGD (0.40) | HTTALDH1A1POLBTDP1SIRT2 | |
| SCHEMBL23208944 | 0.76 | MTNR1A (0.35) | HTTALDH1A1POLBTDP1NQO2 | |
| SCHEMBL29970846 | 0.76 | MTNR1A (0.35) | HTTALDH1A1POLBTDP1NQO2 | |
| SCHEMBL7321008 | 0.76 | CYP1A2 (0.44) | HTTALDH1A1POLBTDP1SIRT2 | |
| SCHEMBL1460108 | 0.76 | POLB (0.50) | HTTALDH1A1POLBTDP1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4703362-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4582423-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| CN-120077041-A | Tricyclic derivative compounds and use thereof | 韩美药品株式会社 | 2025-05-30 | — | — | CN | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025061141-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED PHARMACOKINETIC PROPERTIES | 成都思倍博医药科技有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2024222889-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | 成都思倍博医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024080788-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | 한미약품 주식회사 | 2024-04-18 | — | — | WO | disclosed |
| US-8962651-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962651-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2816023-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-24 | — | — | EP | disclosed |
| WO-2014164968-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014159559-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275154-A1 | Novel Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| US-20140275154-A1 | Novel Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| EP-2397481-B1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | PHARMADESIGN INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2397481-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | Pharmadesign, Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110294857-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | NB HEALTH LABORATORY CO. LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275154-A1 | Novel Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HTT 4838/4885ALDH1A1 415/4885POLB 1462/4885 |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | HTT 4592/4885ALDH1A1 528/4885POLB 180/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | HTT 2985/4885ALDH1A1 4369/4885POLB 3348/4885 |
| US-20110294857-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON | CSNK1A1, CSNK1G1, CSNK2A1 | HTT 1750/4885ALDH1A1 1385/4885POLB 2270/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HTT 2985/4885ALDH1A1 4369/4885POLB 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.